{"id":"live-smallpox-vaccine","safety":{"commonSideEffects":[{"rate":"~100","effect":"Vaccination site reaction (erythema, edema, pustule formation)"},{"rate":"10-50","effect":"Fever"},{"rate":"5-30","effect":"Myalgia/malaise"},{"rate":"5-10","effect":"Lymphadenopathy"},{"rate":"<1","effect":"Serious adverse events (myocarditis, encephalitis, progressive vaccinia)"}]},"_chembl":null,"_dailymed":{"setId":"f8b2634b-ccd7-4a42-8db3-26ba9e9627e6","title":"ACAM2000 (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION DILUENT FOR ACAM2000 (DILUENT FOR SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) SOLUTION [EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live vaccinia virus, a related orthopoxvirus that cross-protects against smallpox infection. Upon administration, the virus replicates in host cells, triggering both humoral (antibody) and cellular (T-cell) immune responses. This generates immunological memory that prevents or significantly reduces severity of smallpox infection upon exposure to the natural virus.","oneSentence":"Live Smallpox Vaccine stimulates adaptive immune responses by introducing live attenuated vaccinia virus to generate protective antibodies and cell-mediated immunity against smallpox.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:37:37.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smallpox prevention and post-exposure prophylaxis"},{"name":"Biodefense/emergency preparedness against smallpox"}]},"trialDetails":[{"nctId":"NCT05740982","phase":"PHASE2","title":"A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-22","conditions":"Monkeypox","enrollment":450},{"nctId":"NCT05734508","phase":"PHASE4","title":"Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-23","conditions":"Monkeypox","enrollment":500},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT06366672","phase":"EARLY_PHASE1","title":"Evaluating the Human Immune Response to the JYNNEOS Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-06-10","conditions":"Vaccinia, Virus Diseases","enrollment":20},{"nctId":"NCT06771479","phase":"PHASE1","title":"A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-01-22","conditions":"Monkeypox","enrollment":120},{"nctId":"NCT00437021","phase":"PHASE1, PHASE2","title":"MVA Post-Event: Administration Timing and Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-04-16","conditions":"Smallpox","enrollment":226},{"nctId":"NCT06223919","phase":"PHASE3","title":"Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2023-12-16","conditions":"Monkeypox","enrollment":8686},{"nctId":"NCT02977715","phase":"PHASE3","title":"JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-02-23","conditions":"Monkeypox Virus Infection","enrollment":1600},{"nctId":"NCT05512949","phase":"PHASE2","title":"Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-09","conditions":"Monkeypox","enrollment":229},{"nctId":"NCT05522296","phase":"","title":"Break-through Infection Following Mpox vaccinatIon","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2022-09-12","conditions":"Mpox","enrollment":3125},{"nctId":"NCT05513313","phase":"","title":"Assessment of Myocarditis After Replication-Deficient Smallpox Immunization","status":"NOT_YET_RECRUITING","sponsor":"Womack Army Medical Center","startDate":"2029-03","conditions":"Myopericarditis, Small Pox","enrollment":2350},{"nctId":"NCT05846243","phase":"PHASE2, PHASE3","title":"Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2021-10-01","conditions":"Smallpox, Monkeypox, Cowpox","enrollment":334},{"nctId":"NCT05762523","phase":"PHASE1","title":"Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2019-05-18","conditions":"Smallpox, Monkeypox, Cowpox","enrollment":60},{"nctId":"NCT01913353","phase":"PHASE3","title":"A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2015-03","conditions":"18-42 Year Old Healthy Vaccinia-naïve Subjects","enrollment":440},{"nctId":"NCT00133575","phase":"PHASE1, PHASE2","title":"ACAM 3000 MVA at Harvard Medical School","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Smallpox","enrollment":72},{"nctId":"NCT00082446","phase":"PHASE1","title":"Combination Study With MVA BN and Dryvax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"Smallpox","enrollment":91},{"nctId":"NCT00050505","phase":"PHASE2","title":"Expanded Dryvax Dilution Study in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-10","conditions":"Smallpox","enrollment":927}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Live Smallpox Vaccine","genericName":"Live Smallpox Vaccine","companyName":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","companyId":"federal-budgetary-research-institution-state-research-center-of-virology-and-bio","modality":"Biologic","firstApprovalDate":"","aiSummary":"Live Smallpox Vaccine stimulates immune response by introducing live attenuated vaccinia virus to generate protective antibodies and cell-mediated immunity against smallpox. Used for Smallpox prevention in at-risk populations, Post-exposure prophylaxis following smallpox exposure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}